The Kassiou Research Group
Medicinal Chemistry & Drug Discovery
|
Publications |
|
Articles in refereed journals. 2013 | 2012
|
2011 | 2010 | 2009-2000 | 1999-1991 The development of CNS-active LRRK2 inhibitors
using property-directed optimisation Kavanagh ME, Doddareddy MR, Kassiou M Bioorg. Med. Chem. Lett. (in press). DOI: 10.1016/j.bmcl.2013.04.086 The synthesis and pharmacological evaluation of
adamantane-derived indoles: novel cannabimimetic drugs of abuse Banister SD, Wilkinson SM, Longworth M, Stuart J,
Apetz N, English K, Brooker L, Goebel C, Hibbs DE, Glass M, Connor M,
McGregor IS, Kassiou M ACS Chem. Neurosci. (in
press). DOI: 10.1021/cn400035r The translocator protein (TSPO): A novel target
for cancer chemotherapy Austin CJD, Kahlert J, Kassiou M, Rendina LM Int. J. Biochem. Cell Biol. (2013), 45(7),
1212-1216. DOI: 10.1016/j.biocel.2013.03.004 The development of radiotracers for imaging sigma
(σ) receptors in the central nervous system (CNS) using positron
emission tomography (PET) Banister SD, Manoli M, Kassiou M J. Label. Compd. Radiopharm. (2013),
56(3-4), 215-224. DOI: 10.1002/jlcr.3010 [18F]DPA-714: Direct Comparison with [11C]PK11195
in a Model of Cerebral Ischemia in Rats Boutin H, Prenant C, Maroy R, Galea J, Greenhalgh
AD, Smigova A, Cawthorne C, Julyan P, Wilkinson SM, Banister SD, Brown G,
Herholz K, Kassiou M, Rothwell NJ PLoS ONE (2013), 8(2): e56441. DOI: 10.1371/journal.pone.0056441 Metabolism and Quantification of [18F]DPA-714,
a New TSPO Positron Emission Tomography Radioligand Peyronneau M-A, Saba W, Goutal S, Damont A, Dolle
F, Kassiou M, Bottlaender M, Valette H Drug Metab. Dispos. (2013), 41(1),
122-131. DOI: 10.1124/dmd.112.046342 Improved accessibility to the desoxy analogues of
Δ9-tetrahydrocannabinol and cannabidiol Wilkinson SM, Price J, Kassiou M Tetrahedron Lett. (2013), 54(1), 52-54. DOI: 10.1016/j.tetlet.2012.10.080 2012 Molecular Imaging of Microglial Activation in
Amyotrophic Lateral Sclerosis Corcia P, Tauber C, Vercoullie J, Arlicot N,
Prunier C, Praline J, Nicolas G, Venel Y, Hommet C, Baulieu J-L, Cottier J-P,
Roussel C, Kassiou M, Guilloteau D, Ribeiro M-J PLoS ONE (2012) 7(12): e52941. DOI: 10.1371/journal.pone.0052941 A σ1 receptor pharmacophore derived from a
series of N-substituted Banister SD, Manoli M, Doddareddy MR, Hibbs DE,
Kassiou M Bioorg. Med. Chem. Lett. (2012),
22(19), 6053-6058. DOI: 10.1016/j.bmcl.2012.08.046 Inhibition of human recombinant T-type calcium
channels by N-arachidonoyl
serotonin Gilmore AJ, Heblinski M, Reynolds A, Kassiou M,
Connor M Br. J. Pharmacol. (2012), 167(5), 1076-1088.
DOI:
10.1111/j.1476-5381.2012.02047.x Synthesis
and Biological Evaluation of Adenosines with Heterobicyclic and Polycyclic N6-Substituents as Adenosine A1
Receptor Agonists Gosling
JI, Baker SP, Haynes JM, Kassiou M, Pouton CW, Warfe L, White PJ, Scammells
PJ ChemMedChem (2012), 7(7),
1191-1201. DOI: 10.1002/cmdc.201200208 Exploration
of ring size in a series of cyclic vicinal diamines with σ1
receptor affinity Moussa
IA, Banister SD, Manoli M, Doddareddy MR, Cui J, Mach RH, Kassiou M Bioorg. Med. Chem. Lett. (2012),
22(17), 5493-5497. DOI: 10.1016/j.bmcl.2012.07.026 A
practical, multigram synthesis of the
2-(2-(4-alkoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (DPA) class of high affinity
translocator protein (TSPO) ligands Banister
SD, Wilkinson SM, Hanani R, Reynolds AJ, Hibbs DE, Kassiou M Tetrahedron Lett. (2012), 53(29),
3780-3783. DOI: 10.1016/j.tetlet.2012.05.044 7-Azabicyclo[2.2.1]heptane as a scaffold for the
development of selective sigma-2 (σ2) receptor ligands Banister SD, Rendina LM, Kassiou M Bioorg. Med. Chem. Lett. (2012),
22(12), 4059-4063. DOI: 10.1016/j.bmcl.2012.04.077 The
non-peptide oxytocin receptor agonist WAY 267,464: receptor binding profile,
prosocial effects and distribution of c-Fos expression in adolescent rats Hicks
C, Jorgensen W, Brown C, Fardell J, Koehbach J, Gruber CW, Kassiou M, Hunt
GE, McGregor IS J.
Neuroendocrinol. (2012),
24(7), 1012-1029. DOI: 10.1111/j.1365-2826.2012.02311.x Is There Any Correlation Between Binding and
Functional Effects at the Translocator Protein (TSPO) (18 kDa)? Scarf AM, Auman KM,
Kassiou M. Curr. Mol. Med. (2012), 12(4), 387-397. http://bit.ly/KN9ZlT Evidence for Complex Binding Profiles and Species
Differences at the Translocator Protein (TSPO) (18 kDa) Scarf AM, Luus C, Da Pozzo E, Selleri
S, Guarino C, Martini CM, Ittner L, Kassiou M Curr. Mol. Med. (2012), 12(4), 488-493. http://bit.ly/M5l4LM The therapeutic potential of sigma (σ)
receptors for the treatment of central nervous system diseases: evaluation of
the evidence Banister
SD, Kassiou M Curr. Pharm. Des. (2012), 18(7),
884-901. DOI: 10.2174/138161212799436539 Consequences
of linker length alteration of the α7 nicotinic acetylcholine receptor
(nAChR) agonist, SEN12333 Beinat
C, Banister SD, van Prehn S, Doddareddy MR, Hibbs D, Sako M, Chebib M, Tran T,
Al-Muhtasib N, Xiao Y, Kassiou M Bioorg. Med.
Chem. Lett.
(2012), 22(7), 2380-2384. DOI:10.1016/j.bmcl.2012.02.052 Radiation
dosimetry and biodistribution of the TSPO ligand [11C]-DPA-713 in humans Endres
CJ, Coughlin JM, Gage KL, Watkins CC, Kassiou M, Pomper MG J. Nucl. Med. (2012), 53(2),
330-335. DOI:10.2967/jnumed.111.094565 Effects
of Translocator Protein (18 kDa) Ligands on Microglial Activation and
Neuronal Death in the Quinolinic-Acid-Injected Rat Striatum Leaver
KR, Reynolds A, Bodard S, Guilloteau D, Chalon S, Kassiou M ACS Chem.
Neurosci.
(2012), 3(2), 114-119. DOI:10.1021/cn200099e Initial evaluation in healthy humans of [18F]DPA-714,
a potential PET biomarker for neuroinflammation Arlicot N, Vercouillie J, Ribeiro M-J, Tauber C,
Venel Y, Baulieu J-L, Maia S, Corcia P, Stabin MG, Reynolds A, Kassiou M,
Guilloteau D Nucl. Med. Biol. (2012), 39(4), 570-578. DOI: 10.1016/j.nucmedbio.2011.10.012 Synthesis
and cellular uptake of boron-rich pyrazolopyrimidines: exploitation of the translocator
protein for the efficient delivery of boron into human glioma cells Crossley
EL, Issa F, Scarf AM, Kassiou M, Rendina LM Chem. Commun. (2011), 47(44),
12179-12181. DOI:10.1039/c1cc14587h Synthesis
and in vivo evaluation of [18F]N-(2-benzofuranylmethyl)-N'-[4-(2-fluoroethoxy)benzyl]piperazine,
a novel σ1 receptor PET imaging agent Moussa
IA, Banister SD, Giboureau N, Meikle SR, Kassiou M Bioorg. Med.
Chem. Lett.
(2011), 21(22), 6820-6823. DOI:10.1016/j.bmcl.2011.09.028 Effects
of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine
σ1 receptor ligands Moussa
IA, Banister SD, Akladios FN, Chua SW, Kassiou M Bioorg. Med.
Chem. Lett.
(2011), 21(19), 5707-5710. DOI:10.1016/j.bmcl.2011.08.029 N-Arylalkyl-2-azaadamantanes
as cage-expanded polycarbocyclic sigma (σ) receptor ligands Banister
SD, Yoo DT, Chua SW, Cui J, Mach RH, Kassiou M Bioorg. Med.
Chem. Lett.
(2011), 21(18), 5289-5292. DOI:10.1016/j.bmcl.2011.07.028 Synthesis
of 6-[18F]fluoro-PBR28, a novel radiotracer for imaging the TSPO
18 kDa with PET Damont
A, Boisgard R, Kuhnast B, Lemée F, Raggiri G, Scarf AM, Da Pozzo E, Selleri
S, Martini C, Tavitian B, Kassiou M, Dollé F Bioorg. Med.
Chem. Lett.
(2011), 21(16), 4819-4822. DOI:10.1016/j.bmcl.2011.06.048 Resilience
and reduced c-Fos expression in P2X7 receptor knockout mice exposed to
repeated forced swim test Boucher
AA, Arnold JC, Hunt GE, Spiro A, Spencer J, Brown C, McGregor IS, Bennett MR,
Kassiou M Neuroscience (2011), 189,
170-177. DOI:10.1016/j.neuroscience.2011.05.049 Brain
inflammation is induced by co-morbidities and risk factors for stroke Drake
C, Boutin H, Jones MS, Denes A, McColl BW, Selvarajah JR, Hulme S, Georgiou
RF, Hinz R, Gerhard A, Brain Behav.
Immun.
(2011), 25(6), 1113-1122. DOI:10.1016/j.bbi.2011.02.008 Boron
in drug discovery: carboranes as unique pharmacophores in biologically active
compounds Issa
F, Kassiou M, Rendina LM Chem. Rev. (2011), 111(9),
5701-5722. DOI:10.1021/cr2000866 The
translocator protein Scarf
AM, Kassiou M J. Nucl. Med. (2011), 52(5),
677-680. DOI:10.2967/jnumed.110.086629 Molecular
hybridization of 4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecane-3-ol
with sigma (σ) receptor ligands modulates off-target activity and
subtype selectivity Banister
SD, Moussa IA, Jorgensen WT, Chua SW, Kassiou M Bioorg. Med.
Chem. Lett.
(2011), 21(12), 3622-3626. DOI:10.1016/j.bmcl.2011.04.098 Trishomocubane
as a scaffold for the development of selective dopamine transporter (DAT)
ligands Banister
SD, Moussa IA, Beinat C, Reynolds AJ, Schiavini P, Jorgensen WT, Kassiou M Bioorg. Med.
Chem. Lett.
(2011), 21(1), 38-41. DOI:10.1016/j.bmcl.2010.11.075 Reduced PBR/TSPO Expression After Minocycline Treatment in a
Rat Model of Focal Cerebral Ischemia: A PET Study Using [18F]DPA-714 Martín A, Boisgard R, Kassiou M, Dollé F, Tavitian B. Mol. Imaging Biol. (2011) 13,
10-15. DOI: 10.1007/s11307-010-0324-y Insights
into structure-activity relationships and CNS therapeutic applications of NR2B
selective antagonists Beinat
C, Banister S, Moussa I, Reynolds AJ, McErlean CSP, Kassiou M Curr. Med. Chem. (2010), 17(34),
4166-4190. DOI:10.2174/092986710793348572 11-{[2-(3-Fluorophenyl)ethyl](methyl)amino}pentacyclo[5.4.0.02,6.03,10.05,9]undecan-8-one Banister
SD, Clegg JK, Hanani R, Kassiou M Acta Crystallogr., Sect. E: Struct. Rep. Online (2010), E66(10), o2693. DOI:10.1107/S1600536810038523 PET
radioligands for the vesicular acetylcholine transporter (VAChT) Giboureau
N, Som IM, Boucher-Arnold A, Guilloteau D, Kassiou M Curr. Top. Med.
Chem.
(2010), 10(15), 1569-1583. Pyrazolo[1,5-a]pyrimidine
acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa
translocator protein (TSPO) Reynolds
A, Hanani R, Hibbs D, Damont A, Da Pozzo E, Selleri S, Dolle F, Martini C,
Kassiou M Bioorg. Med.
Chem. Lett.
(2010), 20(19), 5799-5802. DOI:10.1016/j.bmcl.2010.07.135 Development
of Vesicular Acetylcholine Transporter Ligands: molecular probes for
Alzheimer's disease Giboureau
N, Aumann KM, Beinat C, Kassiou M Curr. Bioact.
Compd.
(2010), 6(3), 129-155. DOI:10.2174/157340710793237353 Boronated
phosphonium salts containing arylboronic acid, closo-carborane, or
nido-carborane: synthesis, x-ray diffraction, in vitro cytotoxicity, and
cellular uptake Morrison
DE, Issa F, Bhadbhade M, Groebler L, Witting PK, Kassiou M, Rutledge PJ,
Rendina LM J. Biol. Inorg.
Chem.
(2010), 15(8), 1305-1318. DOI:10.1007/s00775-010-0690-6 Design,
Synthesis, and Structure-Affinity Relationships of Regioisomeric N-Benzyl
Alkyl Ether Piperazine Derivatives as σ-1 Receptor Ligands Moussa IA,
Banister SD, Beinat C, Giboureau N, Reynolds AJ, Kassiou M J. Med. Chem. (2010), 53(16), 6228-6239. DOI:10.1021/jm100639f Fluorine-18
chemistry for PET: a concise introduction Banister S,
Roeda D, Dolle F, Kassiou M Curr. Radiopharm. (2010), 3(2), 68-80. DOI:10.2174/1874471011003020068 The development
of PET radioligands for imaging the translocator protein (18 kDa): what have
we learned? Luus C, Hanani
R, Reynolds A, Kassiou M J. Label. Compd. Radiopharm. (2010), 53(7),
501-510. DOI:10.1002/jlcr.1752 P2X purinergic
receptor ligands: recently patented compounds Gunosewoyo H,
Kassiou M Expert Opin. Ther. Patents (2010), 20(5),
625-646. DOI:10.1517/13543771003702424 Evaluation of
the PBR/TSPO radioligand [18F]DPA-714 in a rat model of focal
cerebral ischemia Martin A,
Boisgard R, Theze B, Van Camp N, Kuhnast B, Damont A, Kassiou M, Dolle F,
Tavitian B J. Cereb. Blood Flow Metab. (2010), 30(1),
230-241. DOI:10.1038/jcbfm.2009.205 Oxo-bridged
isomers of aza-trishomocubane sigma (σ) receptor ligands: Synthesis, in
vitro binding, and molecular modeling Banister SD,
Moussa IA, Jordan MJT, Coster MJ, Kassiou M Bioorg. Med.
Chem. Lett.
(2010), 20(1), 145-148. DOI:10.1016/j.bmcl.2009.11.019 Attenuation correction for the large
non-human primate brain using microPET Naidoo-Variawa S,
Lehnert W, Kassiou M, Banati R, Meikle SR Phys. Med. Biol. (2010), 55(8), 2351–2363. DOI: 10.1088/0031-9155/55/8/015 Extracellular
Loops 2 and 4 of GLYT2 Are Required for N-Arachidonylglycine Inhibition of
Glycine Transport Edington AR,
McKinzie AA, Reynolds AJ, Kassiou M, Ryan RM, Vandenberg RJ J. Biol. Chem. (2009), 284(52),
36424-36430. DOI:10.1074/jbc.M109.017509 Recent advances
in the Mitsunobu reaction. Modifications and applications to biologically
active molecules Reynolds AJ,
Kassiou M Curr. Org. Chem. (2009), 13(16), 1610-1632. Oral
pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces
subtle symptomatic relief but not neuroprotection Leaver KR,
Allbutt HN, Creber NJ, Kassiou M, Henderson, JM Brain Res. Bull. (2009), 80(6), 397-402. DOI:10.1016/j.brainresbull.2009.08.013 Water-soluble
phosphonium salts containing 1,12-dicarba-closo-dodecaborane Ioppolo JA,
Kassiou M, Rendina LM Tetrahedron Lett. (2009), 50(47), 6457-6461.
DOI:10.1016/j.tetlet.2009.08.112 18F-ZW-104: a new radioligand for imaging neuronal nicotinic
acetylcholine receptors-in vitro binding properties and PET studies in
baboons Valette, Heric;
Xiao, Yingxiang; Peyronneau, Marie-Anne; Damont, Annelaure; Kozikowski, Alan
P.; Wei, Zhi-Liang; Kassiou, Michael; Kellar, Kenneth J.; Dolle, Frederic;
Bottlaender, Michel J. Nucl. Med. (2009), 50(8), 1349-1355. DOI:10.2967/jnumed.108.061374 Initial
evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans Endres CJ,
Pomper MG, James M, Uzuner O, Hammoud DA, Watkins CC, Reynolds A, Hilton J,
Dannals RF, Kassiou M J. Nucl. Med. (2009), 50(8), 1276-1282. DOI:10.2967/jnumed.109.062265 Radiolabelled
molecules for imaging the translocator protein (18 kDa) using positron
emission tomography Dolle F, Luus
C, Reynolds A, Kassiou M Curr. Med. Chem. (2009), 16(22), 2899-2923.
DOI:10.2174/092986709788803150 Purinergic P2X7
receptor antagonists: Chemistry and fundamentals of biological screening Gunosewoyo H,
Coster MJ, Bennett MR, Kassiou M Bioorg. Med. Chem. (2009), 17(14), 4861-4865.
DOI:10.1016/j.bmc.2009.05.083 Comparative
evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714,
and 11C-PK11195 in a rat model of acute neuroinflammation Chauveau F, Van
Camp N, Dolle F, Kuhnast B, Hinnen F, Damont A, Boutin H, James M, Kassiou M,
Tavitian B J. Nucl. Med. (2009), 50(3), 468-476. DOI:10.2967/jnumed.108.058669 Behavioural
effects of a selective NMDA NR1A/2B receptor antagonist in rats with
unilateral 6-OHDA+parafascicular lesions Truong L,
Allbutt HN, Coster MJ, Kassiou M, Henderson JM Brain Res. Bull. (2009), 78(2-3), 91-96. DOI:10.1016/j.brainresbull.2008.10.004 Evaluation of
behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the
unilateral 6-OHDA lesion rat model Warraich ST,
Allbutt HN, Billing R, Radford J, Coster MJ, Kassiou M, Henderson JM Brain Res. Bull. (2009), 78(2-3), 85-90. DOI:10.1016/j.brainresbull.2008.08.023 Challenges in
molecular imaging of Parkinson's disease: A brief overview Kassiou M,
Banati R, Holsinger RMD, Meikle S Brain Res. Bull. (2009), 78(2-3), 105-108. DOI:10.1016/j.brainresbull.2008.08.006 The
Translocator Protein (18 kDa): Central Nervous System Disease and Drug Design Scarf AM,
Ittner LM, Kassiou M J. Med. Chem. (2009), 52(3), 581-592. DOI:10.1021/jm8011678 [11C]-DPA-713
and [18F]-DPA-714 as New PET Tracers for TSPO: A Comparison with [11C]-(R)-PK11195 in a Rat Model of Herpes
Encephalitis. Doorduin
J, Klein HC, Dierckx RA, James M,
Kassiou M, de Vries EFJ. Mol. Imaging Biol. (2009), 11(6), 386-398. DOI: 10.1007/s11307-009-0211-6 Neuroprotective
effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model
of Parkinson's disease Leaver KR,
Allbutt HN, Creber NJ, Kassiou M, Henderson JM Clin. Exptl. Pharmacol. Physiol. (2008),
35(11), 1388-1394. DOI:10.1111/j.1440-1681.2008.05046.x Radiosynthesis
of [18F]DPA-714, a selective radioligand for imaging the
translocator protein (18 kDa) with PET Damont A,
Hinnen F, Kuhnast B, Schollhorn-Peyronneau M-A, James M, Luus C, Tavitian B,
Kassiou M, Dolle F J. Label. Cmpd. Radiopharm. (2008), 51(7),
286-292. DOI:10.1002/jlcr.1523 Dopamine D1 receptor
imaging in the rodent and primate brain using the isoquinoline (+)-[11C]A-69024
and positron emission tomography Besret L, Dolle
F, Herard A-S, Guillermier M, Demphel S, Hinnen F, Coulon C, Ottaviani M,
Bottlaender M, Hantraye P J. Pharm. Sci. (2008), 97(7), 2811-2819. DOI:10.1002/jps.21168 Synthesis and In Vivo Evaluation of [11C]p-PVP-MEMA
as a PET Radioligand for Imaging Nicotinic Receptors Dolle F, Langle
S, Roger G, Fulton RR, Lagnel-de Bruin B, Henderson DJ, Hinnen F, Paine T,
Coster, MJ, Valette H Aust. J. Chem. (2008), 61(6), 438-445. DOI:10.1071/CH08083 Cubyl amides:
Novel P2X7 receptor antagonists Gunosewoyo H,
Guo JL, Bennett MR, Coster MJ, Kassiou M Bioorg. Med. Chem. Lett. (2008),
18(13), 3720-3723. DOI:10.1016/j.bmcl.2008.05.062 DPA-714, a new
translocator protein-specific ligand: synthesis, radiofluorination, and
pharmacologic characterization James ML,
Fulton RR, Vercoullie J, Henderson DJ, Garreau L, Chalon S, Dolle F, Selleri
S, Guilloteau D, Kassiou M J. Nucl. Med. (2008), 49(5), 814-822. DOI:10.2967/jnumed.107.046151 Behavioural
effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions van Dijk, Addy;
Johnston, Christopher; Allbutt, Haydn; Kassiou, Michael; Henderson, Jasmine Behav. Brain Res. (2008), 190(1), 14-21. DOI:10.1016/j.bbr.2008.02.034 (E)-[125I]-5-AOIBV: a SPECT
radioligand for the vesicular acetylcholine transporter Emond P, Mavel
S, Zea-Ponce Y, Kassiou M, Garreau L, Bodard S, Drossard M-L, Chalon S,
Guilloteau D Nucl. Med. Biol. (2007), 34(8), 967-971. DOI:10.1016/j.nucmedbio.2007.07.011 Ex vivo and in vivo
evaluation of (2R,3R)-5-[18F]-fluoroethoxy- and
fluoropropoxy-benzovesamicol, as PET radioligands for the vesicular
acetylcholine transporter Giboureau N,
Emond P, Fulton RR, Henderson DJ, Chalon S, Garreau L, Roselt P, Eberi S,
Mavel S, Bodard S Synapse (2007), 61(12), 962-970. DOI:10.1002/syn.20450 [11C]-DPA-713:
a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of
neuroinflammation Boutin H,
Chauveau F, Thominiaux C, Gregoire M-C, James ML, Trebossen R, Hantraye P,
Dolle F, Tavitian B, Kassiou M J. Nucl. Med. (2007), 48(4), 573-581. DOI:10.2967/jnumed.106.036764 Positron
emission tomography imaging of neuroinflammation Cagnin A,
Kassiou M, Meikle SR, Banati RB Neurotherapeutics (2007), 4(3), 443-452. DOI:10.1016/j.nurt.2007.04.006 Molecular
probes for P2X7 receptor studies Gunosewoyo H,
Coster MJ, Kassiou M Curr. Med. Chem. (2007), 14(14), 1505-1523.
DOI:10.2174/092986707780831023 Acetylenic
pyridines for use in PET imaging of nicotinic receptors Kozikowski AP,
Chellappan SK, Henderson D, Fulton R, Giboureau N, Xiao Y, Wei Z-L, Guilloteau
D, Emond P, Dolle F ChemMedChem (2007), 2(1), 54-57. DOI:10.1002/cmdc.200600220 Decreased
vesicular acetylcholine transporter and α4β2 nicotinic receptor
density in the rat brain following 192 IgG-saporin immunolesioning Quinlivan M,
Chalon S, Vergote J, Henderson J, Katsifis A, Kassiou M, Guilloteau D Neurosci. Lett. (2007), 415(2), 97-101. DOI:10.1016/j.neulet.2006.08.065 High resolution
imaging of the large non-human primate brain using microPET: A feasibility
study Naidoo-Variawa
S, Hey-Cunningham AJ, Lehnert W, Kench PL, Kassiou M, Banati R, Meikle SR Phys. Med. Biol. (2007), 52(22), 6627-6638.
DOI: 10.1088/0031-9155/52/22/005 Imaging sigma
receptors: applications in drug development Collier TL,
Waterhouse RN, Kassiou M Curr. Pharm. Des. (2007), 13(1), 51-72. Molecular
imaging in drug development Kassiou, M Curr. Pharm. Des. (2007), 13(1), 1. (1R,2S,3R,6S,7R,8S)-Tricyclo[6.2.1.02,7]undeca-4,9-diene-3,6-diol Banister SD,
Clegg JK, Coster MJ, Jolliffe KA, Kassiou M Acta Crystallogr., Sect. E: Struct. Rep.
Online (2007), E63(1), o92-o93.
DOI:10.1107/S1600536806051002 Trishomocubanes:
Novel σ ligands modulate cocaine-induced behavioral effects Liu X, Banister
SD, Christie MJ, Banati R, Meikle S, Coster MJ, Kassiou M Eur. J. Pharmacol. (2007), 555(1), 37-42. DOI:10.1016/j.ejphar.2006.10.020 2006 Development of
ligands for the peripheral benzodiazepine receptor James ML,
Selleri S, Kassiou M Curr. Med. Chem. (2006), 13(17), 1991-2001.
DOI:10.2174/092986706777584979 Synthesis and
in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular
acetylcholine transporter ligands Assaad T, Mavel
S, Parsons SM, Kruse S, Galineau L, Allouchi H, Kassiou M, Chalon S,
Guilloteau D, Emond P Bioorg. Med. Chem. Lett. (2006),
16(10), 2654-2657. DOI:10.1016/j.bmcl.2006.02.033 Improved synthesis
of the peripheral benzodiazepine receptor ligand [11C]DPA-713
using [11C]methyl triflate Thominiaux C,
Dolle F, James ML, Bramoulle Y, Boutin H, Besret L, Gregoire M-C, Valette H,
Bottlaender M, Tavitian, B Appl. Rad. Isotop. (2006), 64(5), 570-573. DOI:10.1016/j.apradiso.2005.12.003 Developing a
preclinical model of Parkinson's disease: A study of behaviour in rats with
graded 6-OHDA lesions Truong L,
Allbutt H, Kassiou M, Henderson JM Behav. Brain Res. (2006), 169(1), 1-9. DOI:10.1016/j.bbr.2005.11.026 Synthesis and
Radiolabelling of Ipratropium and Tiotropium for Use as PET Ligands in the
Study of Inhaled Drug Deposition Issa F, Kassiou
M, Chan H-K, McLeod MD Aust. J. Chem. (2006), 59(1), 53-58. DOI:10.1071/CH05303 Synthesis and
in vitro evaluation of novel derivatives of diphenyl sulfide as serotonin
transporter ligands Vercouillie J,
Mavel S, Galineau L, Ragusa T, Innis R, Kassiou M, Chalon S, Dolle F, Besnard
J-C, Guilloteau D Bioorg. Med. Chem. Lett. (2006), 16(5),
1297-1300. DOI:10.1016/j.bmcl.2005.11.066 Radiosynthesis
of (E)-N-(2-[11C]methoxybenzyl)-3-phenyl-acrylamidine, a
novel subnanomolar NR2B subtype-selective NMDA receptor antagonist Thominiaux C,
de Bruin B, Bramoulle Y, Hinnen F, Demphel S, Valette H, Bottlaender M,
Besret L, Kassiou M, Dolle F Appl. Rad. Isotop. (2006), 64(3), 348-354. DOI:10.1016/j.apradiso.2005.08.005 Clinical
evidences of microglial activation in neurodegenerative dementia Cagnin A,
Kassiou M, Meikle SR, Banati RB Acta. Neurologic. Scand. (2006),
114(S185), 107-114. DOI:
10.1111/j.1600-0404.2006.00694.x 2005 Sequential 123I-iododexetimide
scans in temporal lobe epilepsy: comparison with neuroimaging scans (MR
imaging and 18F-FDG PET imaging) Mohamed A,
Eberl S, Fulham MJ, Kassiou M, Zaman A, Henderson D, Beveridge S, Constable
C, Lo SK Eur. J. Nuc. Med. Mol. Imaging (2005), 32(2),
180-185. DOI: 10.1007/s00259-004-1654-2 Small animal
SPECT and its place in the matrix of molecular imaging technologies Meikle SR,
Kench P, Kassiou M, Banati RB Phys. Med. Biol. (2005), 50(22), R45-R61. DOI:10.1088/0031-9155/50/22/R01 Synthesis and
in vivo evaluation of a novel peripheral benzodiazepine receptor PET
radioligand James ML,
Fulton RR, Henderson DJ, Eberl S, Meikle SR, Thomson S, Allan RD, Dolle F,
Fulham MJ, Kassiou M Bioorg. Med. Chem. (2005), 13(22), 6188-6194.
DOI:10.1016/j.bmc.2005.06.030 Synthesis and
in vivo evaluation of a new PET radioligand for studying sigma-2 receptors Kassiou M,
Dannals RF, Liu X, Wong DF, Ravert HT, Scheffel UA Bioorg. Med. Chem. (2005), 13(11), 3623-3626.
DOI:10.1016/j.bmc.2005.03.039 Ligands for peripheral
benzodiazepine binding sites in glial cells Kassiou M,
Meikle SR, Banati RB Brain Res. Rev. (2005), 48(2), 207-210. DOI:10.1016/j.brainresrev.2004.12.010 Influence of
trishomocubanes on sigma receptor binding of N-(1-benzyl-piperidin-4-yl)-4-[123I]iodobenzamide in vivo in the rat brain Liu X, Mattner
F, Katsifis A, Christie M, Kassiou M Med. Chem. (2005), 1(1), 31-38. DOI:10.2174/1573406053402541 Synthesis and
in vitro evaluation of new benzovesamicol analogs as potential imaging probes
for the vesicular acetylcholine transporter Zea-Ponce Y,
Mavel S, Assaad T, Kruse SE, Parsons SM, Emond P, Chalon S, Giboureau N,
Kassiou M, Guilloteau D Bioorg. Med. Chem. (2005), 13(3), 745-753. DOI:10.1016/j.bmc.2004.10.043 2004 Radiosynthesis
and in vivo evaluation of [11C]Ro-647312: A novel NR1/2B subtype selective
NMDA receptor radioligand Dolle F,
Valette H, Demphel S, Coulon C, Ottaviani M, Bottlaender M, Kassiou M J. Label. Cmpd. Radiopharm. (2004),
47(13), 911-920. Development of
radioligands for in vivo imaging of GABAA-benzodiazepine receptors Katsifis A,
Kassiou M Mini-Rev. Med. Chem. (2004), 4(8),
909-921. Radiosynthesis
and pharmacological evaluation of [11C]EMD-95885: a high affinity
ligand for NR2B-containing NMDA receptors Roger G, Dolle
F, de Bruin B, Liu X, Besret L, Bramoulle Y, Coulon C, Ottaviani M,
Bottlaender M, Valette H Bioorg. Med. Chem. (2004), 12(12), 3229-3237.
DOI:10.1016/j.bmc.2004.03.065 The role of positron
emission tomography in the discovery and development of new drugs; As studied
in laboratory animals Roselt P,
Meikle S, Kassiou M Eur. J. Drug Metab. Pharmacokinet. (2004),
29(1), 1-6. DOI:10.1007/BF03190567 3-Pyridyl
ethers as SPECT radioligands for imaging nicotinic acetylcholine receptors Henderson DJ,
Eberl S, Thomson S, Smith A, Allan RD, Fulham MJ, Loiacono R, Kassiou M Appl. Rad. Isotop. (2004), 60(5), 669-676. DOI:10.1016/j.apradiso.2004.01.002 Synthesis,
radiosynthesis and In vivo evaluation of
5-[3-(4-Benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[11C]one,
as a potent NR1A/2B subtype selective NMDA PET radiotracer Roger G, Lagnel
B, Besret L, Bramoulle Y, Coulon C, Ottaviani M, Kassiou M, Bottlaender M,
Valette H, Dolle F Bioorg. Med. Chem. (2003), 11(24), 5401-5408.
DOI:10.1016/j.bmc.2003.09.036 Synthesis and evaluation of iodine-123 labelled tricyclic tropanes as
radioligands for the serotonin transporter Quinlivan M,
Mattner F, Papazian V, Zhou J, Katsifis A, Emond P, Chalon S, Kozikowski A,
Guilloteau D, Kassiou M Nucl. Med. Biol. (2003), 30(7), 741-746. DOI:10.1016/S0969-8051(03)00076-3 PET radiochemistry in drug development and evaluation Kassiou M, Katsifis A Chem. Aust. (2003), 70(5), 10-12. Pharmacological evaluation of (S)-8-[123I]iodobretazenil:
a radioligand for in vivo studies
of central benzodiazepine receptors Katsifis A, Mardon K, Mattner F, Loc'h C, McPhee ME, Dikic B, Kassiou
M, Ridley DD Nucl. Med. Biol. (2003), 30(2), 191-198. DOI:10.1016/S0969-8051(02)00394-3 Preparation of a bromine-76 labelled analogue of epibatidine: a potent
ligand for nicotinic acetylcholine receptor studies Kassiou M, Loc'h C, Dolle F, Musachio JL, Dolci L, Crouzel C, Dannals
RF, Maziere B Appl. Rad. Isotop. (2002), 57(5), 713-717. DOI:10.1016/S0969-8043(02)00187-2 Pharmacological evaluation of a Br-76 analog of epibatidine: A potent
ligand for studying brain nicotinic acetylcholine receptors Kassiou M, Bottlaender M, Loc'h C, Dolle F, Musachio JL, Coulon C,
Ottaviani M, Dannals RF, Maziere B Synapse (2002), 45(2), 95-104. DOI:10.1002/syn.10087 (+)-[76Br]A-69024: a non-benzazepine radioligand for studies
of dopamine D1 receptors using PET Kassiou M, Loc'h C, Bottlaender M, Mardon K, Ottaviani M, Coulon C,
Katsifis A, Maziere B Nucl. Med. Biol. (2002),
29(3), 295-302. DOI:10.1016/S0969-8051(01)00306-7 2001 In vivo imaging of nicotinic receptor upregulation following chronic
(-)-nicotine treatment in baboon using SPECT Kassiou M, Eberl S, Meikle SR, Birrell A, Constable C, Fulham MJ, Wong
DF, Musachio J Nucl. Med. Biol. (2001), 28(2), 165-175. DOI:10.1016/S0969-8051(00)00206-7 Trishomocubanes:
Requirements for σ receptor binding and subtype selectivity Liu X, Kassiou
M, Christie MJ Hambley, TW Aust. J. Chem. (2001), 54(1), 31-36. Pharmacological
evaluation of (+)-2-[123I]A-69024 A radioligand for in vivo
studies of dopamine D1 receptors Kassiou M, Mardon
K, Mattner F, Katsifis A, Dikic B Life Sci. (2001), 69(6), 669-675. DOI:10.1016/S0024-3205(01)01156-0 Trishomocubanes: novel σ-receptor ligands modulate
amphetamine-stimulated [3H]dopamine release Liu X, Samer N, Christie MJ, Kassiou M, Werling LL Eur. J. Pharmacol. (2001), 422(1-3), 39-45. DOI:10.1016/S0014-2999(01)01071-8 2000 X-ray
crystallographic structures of biologically active trishomocubanes of the
types pentacyclo[5.4.0.02,6.03,10.05,9]undecylamines
and 4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecane Hambley, TW,
Knott R, Kassiou M, Christie MJ Aust. J. Chem. (2000), 53(11 & 12),
899-904. Radiosynthesis of
bromine-76 and iodine-123 labelled enantiomers of A-69024: radioligands for
dopamine D1 receptor studies using PET and SPECT Kassiou M, Loc'h C, Katsifis A, Papazian V, Mattner F, Dikic B, Maziere B J. Label. Cmpd. Radiopharm. (2000), 43(4), 339-346. DOI:10.1002/(SICI)1099-1344(20000330)43:4<339::AID-JLCR321>3.0.CO;2-6 The influence of
tomograph sensitivity on kinetic parameter estimation in positron emission
tomography imaging studies in the rat brain Miekle SR,
Eberl S, Fulton RR, Kassiou M, Fulham MJ Nucl. Med. Biol. (2000), 27(6), 617-625. DOI: 10.1016/S0969-8051(00)00105-0 Effects of
streptozotocin-induced diabetes on neuronal sigma receptors in the rat brain Mardon K,
Kassiou M, Donald A Life Sci. (1999), 65(23), PL281-PL286. DOI:10.1016/S0024-3205(99)00521-4 Synthesis and
binding studies of trishomocubanes: novel ligands for σ binding sites Liu X, Kassiou
M, Christie MJ Aust. J. Chem. (1999), 52(7), 653-656. DOI:10.1071/CH99010 A study of
myocardial muscarinic receptors in streptozotocin-induced diabetic rats using
iodine-123 N-methyl-4-iododexetimide Mardon K,
Kassiou M, Katsifis A, Najdovski L Eur. J. Nucl. Med. (1999), 26(7), 743-749. DOI:10.1007/s002590050445 In vitro and in vivo
characterization of [3H]ANSTO-14 binding to the σ1
binding sites Nguyen VH,
Mardon K, Kassiou M, Christie MJ Nucl. Med. Biol. (1999), 26(2), 209-215. DOI:10.1016/S0969-8051(98)00095-X σ-Binding
site ligands inhibit K+ currents in rat locus coeruleus neurons in vitro Nguyen VH,
Ingram SL, Kassiou M, Christie MJ Eur. J. Pharmacol. (1998), 361(1), 157-163. DOI:10.1016/S0014-2999(98)00706-7 Pharmacological
evaluation of [11C]A-84543: an enantioselective ligand for in vivo studies of neuronal nicotinic
acetylcholine receptors Kassiou M,
Scheffel UA, Ravert HT, Mathews WB, Musachio JL, London ED, Dannals RF Life Sci. (1998), 63(1), PL13-PL18. DOI:10.1016/S0024-3205(98)00240-9 Synthesis of
3-[(1-[11C]methyl-2(S)-pyrrolidinyl)methoxy]pyridine
and 3-[(1-[11C]methyl-2(R)-pyrrolidinyl)methoxy]pyridine:
radioligands for in vivo studies of neuronal nicotinic acetylcholine
receptors Kassiou M,
Ravert HT, Mathews WB, Musachio JL, London ED, Dannals RF J. Label. Cmpd. Radiopharm. (1997), 39(5),
425-431. DOI:10.1002/(SICI)1099-1344(199705)39:5<425::AID-JLCR984>3.0.CO;2-R Synthesis and
evaluation of halogenated dibenzodiazepines as muscarinic receptor ligands Kassiou M, Read
R, Shi X-Q Bioorg. Med.Chem. Lett. (1997), 7(7),
799-804. DOI:10.1016/S0960-894X(97)00109-1 1996 Synthesis of iodine-123
labeled analogs of imidazenil and ethylimidazenil for studying benzodiazepine
receptors using SPECT Katsifis A,
Mattner F, Dikic B, Najdovski L, Kassiou M J. Label. Cmpd. Radiopharm. (1996), 38(12),
1121-1132. DOI:10.1002/(SICI)1099-1344(199612)38:12<1121::AID-JLCR948>3.0.CO;2-V Comparison of
binding parameters of σ1 and σ2 binding sites
in rat and guinea pig brain membranes: novel subtype-selective
trishomocubanes Nguyen VH,
Kassiou M, Johnston GAR, Christie MJ Eur. J. Pharmacol. (1996), 311(2-3), 233-240. DOI:10.1016/0014-2999(96)00395-0 Synthesis of
iodine-123 labeled analogs of the partial agonist (S)- and (R)-bretazenil
for the study of CNS benzodiazepine receptors using SPECT Katsifis A,
Mattner F, McPhee M, Kassiou M, Najdovski L, Dikic B J. Label. Cmpd. Radiopharm. (1996), 38(9), 835-845. DOI:10.1002/(SICI)1099-1344(199609)38:9<835::AID-JLCR898>3.0.CO;2-Z Pharmacological
characterization and positron emission tomography evaluation of 4-[76Br]bromodexetimide
and 4-[76Br]bromolevetimide for investigations of central
muscarinic cholinergic receptors Loc’h C,
Kassiou M, Strijckmans V, Bottlaender M, Katsifis A, Schmid L, Maziere M,
Lambrecht RM, Maziere B Nucl. Med. Biol. (1996), 23(3), 235-243. DOI:10.1016/0969-8051(95)02052-7 Radiosynthesis
of [123I]N-methyl-4-iododexetimide
and [123I]N-methyl-4-iodolevetimide:
In vitro and in vivo characterization of binding to muscarinic receptors in
the rat heart Kassiou M,
Mardon M, Katsifis A, Najdovski L, Dikic D, Mattner F, Lambrecht RM, Hicks
RJ, Eu P, Loc’h C Nucl. Med. Biol. (1996), 23(2), 147-53. DOI:10.1016/0969-8051(95)02045-4 Trishomocubanes,
a new class of selective and high affinity ligands for the sigma binding site Kassiou M,
Nguyen V, Knott R, Christie MJ, Hambley T Bioorg. Med. Chem. Lett. (1996), 6(6),
595-600. DOI:10.1016/0960-894X(96)00067-4 Localization of
temporal lobe epileptic foci with iodine-123 iododexetimide cholinergic
neuroreceptor single-photon emission computed tomography Boundy K, Rowe
CC, Black AB, Kitchener MI, Barden L, Sebben R, Kassiou M, Katsifis A,
Lambrecht RM Neurology (1996), 47(4), 1015-1020. In vitro pharmacological properties of 4-bromodexetimide
for muscarinic receptors Strijckmans V,
Coulon C, Kassiou M, Loc’h C, Maziere B Life Sci. (1996), 58(23), PL337-344. DOI: 10.1016/0024-3205(96)00212-3 1995 [3H]A-69024:
a non-benzazepine ligand for in vitro
and in vivo studies of dopamine D1
receptors Kassiou M,
Scheffel U, Ravert HT, Mathews WB, Musachio JL, Lambrecht RM, Dannals RF Nucl. Med. Biol. (1995),
57(23), PL367-PL372. DOI:10.1016/0024-3205(95)02212-2 Human dosimetry
and biodistribution of iodine-123-iododexetimide: A SPECT imaging agent for
cholinergic muscarinic neuroreceptors Boundy KL,
Barnden LR, Rowe CC, Reid M, Kassiou M, Katsifis A, Lambrecht RM J. Nucl. Med. (1995),
36(7), 1332-1338. [11C]A-69024:
a potent and selective non-benzazepine radiotracer for in vivo studies of
dopamine D1 receptors Kassiou M,
Scheffel U, Ravert H, Mathews WB, Musachio JL, Lambrecht RM, Dannals RF Nucl. Med. Biol. (1995),
22(2), 221-6. DOI:10.1016/0969-8051(94)00086-Y Synthesis of [76Br]4-bromodexetimide
and [76Br]4-bromolevetimide: radiotracers for studying muscarinic
cholinergic receptors using PET Kassiou M,
Loc’h C, Strijckmans V, Katsifis A, Lambrecht RM, Maziere M, Maziere B J. Label. Cmpd. Radiopharm. (1995), 36(3), 259-66. DOI:10.1002/jlcr.2580360308 Iodine-123 N-methyl-4-iododexetimide: a new
radioligand for SPET imaging of myocardial muscarinic receptors Hicks RJ,
Kassiou M, Eu P, Katsifis A, Garra M, Power J, Najdovski L, Lambrecht RM Eur. J. Nucl. Med. Mol. Imaging (1995), 22(4), 339-345. DOI: 10.1007/BF00941851 1994 Radiosynthesis
of (±)-1-(2-bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-[11C]-methyl-1,2,3,4-tetrahydroisoquinoline,
[11C]A-69024: a non-benzazepine antagonist for studying dopamine
D1 receptors in vivo using PET Kassiou M,
Mathews WB, Musachio JL, Ravert HT, Lambrecht RM, Dannals RF J. Label. Cmpd. Radiopharm. (1994), 34(5),
431-437. DOI:10.1002/jlcr.2580340505 Synthesis and
stereochemical assignment of 2,5-trans-2',5'-trans-5,5'-dimethylperhydro-2,2'-bipyrimidine
and heterocycles derived from its condensation with formaldehyde Kassiou M, Read
RW Tetrahedron (1994), 50(8), 2497-2506. DOI:10.1016/S0040-4020(01)86966-0 1993 Reactions of
perhydro-2,2'-bipyrimidines with carbonyl compounds bearing α-carbonyl
functionality Craig DC,
Doughty A, Kassiou M, MacIntosh M, Read RW J. Org. Chem. (1993), 58(21), 5753-5758. DOI:10.1021/jo00073a039 1992 Synthesis and
stereochemical assignment of heterocycles derived from (2S*,2'S*,4R*,4'R*,6S*,6'S*)-4,4',6,6'-tetramethylperhydro-2,2'-bipyrimidine Craig DC,
Kassiou M, Read RW J. Org. Chem. (1992), 57(14), 3901-3905. DOI:10.1021/jo00040a033 1991 Unexpected formation of
5,12-dimethyl-3,7,10,14,15,16-tetraazapentacyclo[7.5.1.12,8.15,16.112,15]octadecane,
a novel caged nitrogen heterocycle, and preparation and x-ray crystal
structure of its copper(II) chloride complex Craig DC,
Kassiou M, Read RW J. Chem. Soc., Chem. Commun. (1991), (8),
607-608. DOI:10.1039/c39910000607 Evidence
for equatorial bridging in 2,2'-bis(hexahydropyrimidines), perhydro-4,5,8a,9a-tetraazafluorenes,
and perhydro-3a,4a,7a,8a-tetraazacyclopentanofluorenes through one-bond
carbon-hydrogen coupling Black
DSC, Kassiou M, Read RW J. Org. Chem. (1991), 56(13), 4308-4312. DOI:10.1021/jo00013a046 Preferred
equatorial linkages of hexahydropyrimidine rings in
dodecahydro-2,2'-bipyrimidines Black
DSC, Craig DC, Kassiou M, Read RW Aust. J. Chem. (1991), 44(1), 143-149. DOI:10.1071/CH9910143 |
|
|
